Investor Relations

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

2024.09.16

Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels The recommended Phase 2 dose for givastomig was

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

2024.09.10

- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials - Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients - Randomized Phase 2

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

2024.08.28

Completed divestiture of China operations Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X